Alpha Tau Medical Ltd. (DRTS)
Alpha Tau Medical develops Alpha DaRT, a localized radiation therapy technology for solid tumors. It last closed at $12.09 on Nov 17, up 1.00% on the day. DRTS reports earnings on Thu, Nov 19, 2026. The average 12-month price target from 3 analysts is $22.67 (+87.5% from the last close), with a high of $30.00 and a low of $16.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Key Stats
Last 12 monthsNot reported for this period.
From DRTS's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 9). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on DRTS in the past 90 days. The average target is $22.67, with a high of $30.00 and a low of $16.00, compared with the last close of $12.09.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 11 | Piper Sandler | Upgrade | Buy | $22 |
| Oct 20 | HC Wainwright & Co. | Reiterated | Buy | $16 |
| Sep 3 | Barclays | Target raised | Buy | $17 → $30 |
| Aug 11 | HC Wainwright & Co. | Target raised | Buy | $15 → $16 |
| Jul 16 | HC Wainwright & Co. | Reiterated | Buy | $15 |
Technical Analysis
The stock is 10% below its 20 day and 15% below its 50 day average. It is 9% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 38). The nearest support is the Pivot at $12.00, and the nearest resistance the Pivot R1 at $12.29.
| RSI (14) | 38.18 | Weak, oversold below 30 | Neutral |
| MACD | -0.27 | Below its signal line | Bearish |
| Stochastic | 18.9 | Near the bottom of its range | Oversold |
| ADX (14) | 20.6 | Weak trend | |
| Williams %R | -86.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -237.3 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −10.7% | Change over 10 sessions | Bearish |
| ATR (14) | $0.79 | Typical daily range, 6.5% of price |
| RSI (14) | 48.17 | Middle of its range | Neutral |
| MACD | 0.80 | Below its signal line | Bearish |
| Stochastic | 33.0 | Middle of its range | Neutral |
| ADX (14) | 27.2 | Trending down | |
| Williams %R | -90.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -79.3 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −16.2% | Change over 10 sessions | Bearish |
| ATR (14) | $1.58 | Typical daily range, 13.1% of price |
What happened before
See how DRTS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How DRTS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in DRTS in the last 90 days.
DRTS Institutional Ownership
Full report →- ▲58 buying vs 30 selling
- ▲Shares held by funds +42.2%
- ▲Funds holding +21
- ●Superinvestors: 1 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 95 | 74 | +28.4% |
| In funds' top 10 | 1 | 1 | 0.0% |
| Held by funds | – | – | – |
| New / increased | 34 / 24 | 26 / 18 | +31.8% |
| Reduced / sold out | 16 / 14 | 10 / 6 | +87.5% |
| Put/call ratio | 0.03 | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DRTS is in one of them and how their past DRTS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered DRTS in an article yet. Here's the latest on the wider market.
About Alpha Tau Medical
Alpha Tau Medical is based in Jerusalem, Israel, and develops Alpha DaRT, a localized radiation therapy technology for solid tumors. It uses alpha particles, which travel only short distances, to treat tumors in place. The company is running clinical trials for skin, head and neck, pancreatic and brain tumors, including cancers that are hard to remove surgically or not well served by standard care. Its intended customers are cancer patients and the hospitals and medical centers that treat them.
- Headquarters
- Jerusalem, Israel

